This price target is based on 0 analysts offering 12 month price targets for TSO3 in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a NaN upside from the last price of C$0.00.
The current consensus among 0 contributing investment analysts is to n/a stock in TSO3. This rating has held steady since March 2020, when it changed from a Hold consensus rating.
TSO3 Inc. engages in the research, development, production, maintenance, sale, and licensing of sterilization processes, related consumable supplies, and accessories for heat and moisture sensitive medical devices worldwide. Its principal product is the STERIZONE VP4 sterilizer, a dual sterilant, low temperature sterilization system that utilizes vaporized hydrogen peroxide and ozone that is marketed in Canada and the United States. The company also develops and sells the STERIZONE 125L+ sterilizer, which is designed for terminal sterilization of heat and moisture sensitive medical devices, and is intended for the reprocessing of general instruments, rigid channel instruments, and single/multi-channel rigid endoscopes, as well as short and long single/multi-channel flexible endoscopes. In addition, it provides product development services to medical device manufacturers and others that include hydrogen peroxide and ozone sterilization validation, compatibility testing, medical devices cleaning method development, and medical packaging compatibility verification services. The company was founded in 1998 and is headquartered in Quebec, Canada.